As of 12:49pm ET
| +0.66 / +4.00%|
The 5 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 25.00, with a high estimate of 28.00 and a low estimate of 20.00. The median estimate represents a +45.69% increase from the last price of 17.16.
The current consensus among 6 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.